Citigroup
DICE

Citigroup’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Citigroup’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,752
Closed -$825K – 5876
2023
Q2 		$825K Buy
17,752
+11,597
+188% +$401K ﹤0.01% 2987
2023
Q1 		$176K Sell
6,155
-256
-4% -$7.58K ﹤0.01% 3792
2022
Q4 		$200K Buy
6,411
+1,258
+24% +$41K ﹤0.01% 3722
2022
Q3 		$105K Sell
5,153
-1,799
-26% -$32.8K ﹤0.01% 4074
2022
Q2 		$108K Sell
6,952
-2,957
-30% -$50.9K ﹤0.01% 4188
2022
Q1 		$190K Sell
9,909
-4,023
-29% -$71.8K ﹤0.01% 4103
2021
Q4 		$353K Buy
13,932
+12,626
+967% +$370K ﹤0.01% 4030
2021
Q3 		$43K Buy
+1,306
New +$44.5K ﹤0.01% 4826

Citigroup's DICE Position: Q3 2023 in Review

Citigroup sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 17,752 shares — an estimated $825K sold.

Citigroup first reported a position in DICE in Q3 2021 and held it in 8 quarters. The position peaked at $825K in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • Citigroup reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Citigroup sold 17,752 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $825K.
  • Citigroup first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
  • Citigroup's DICE Therapeutics, Inc. Common Stock position peaked at $825K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Citigroup's 13F filing for Q3 2023, filed 9 Nov 2023.